{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-071896","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.745676+00:00","generated_at":"2026-06-07T09:50:47.925437+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Atara closes expanded tab-cel partnership with Pierre Fabre; receives ~$27M upfront, up to $640M total","bullets":["Pierre Fabre gets development, manufacturing, commercialization rights for tab-cel in US and all remaining markets.","Atara receives ~$27M cash upfront and initial inventory purchase; potential milestones up to $640M total.","Potential $100M in regulatory milestones through BLA approval; significant double-digit tiered royalties on net sales.","Pierre Fabre to reimburse global development costs through BLA transfer; manufacturing transition planned at BLA transfer.","Atara plans to submit tab-cel BLA for PTLD to FDA in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-071896","json":"https://secwatch.observer/filing/0000950170-23-071896.json","markdown":"https://secwatch.observer/filing/0000950170-23-071896.md","text":"https://secwatch.observer/filing/0000950170-23-071896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023071896/0000950170-23-071896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023071896/atra-20231220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:50:47.925437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}